Work

Management of myelodysplastic syndromes: 2008 update.

Year: 2008

Type: review

Abstract: Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic disorders characterized by low blood counts and a tendency to progress to acute myeloid leukemia. Treatment options have increased over the past 10 years, and many new agents are currently being investigated. In this article, we review the diagnosis of MDS, prognostic systems, and treatment options, including supportive care, erythropoiesis-stimulating agents, antithymocyte globulin, lenalidomide, azacitidine, decitabine, intensive chemotherapy, and hematopoietic cell transplantation.

Source: PubMed

Authors: Bart L Scott, Eli Estey

Institutions: University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Heart, Lung, and Blood Institute

Award: Improving Allogenic Transplant Outcomes in Myeloid Malignancies